8635 W. 3rd St. Suite #485-W
Los Angeles, CA 90048
(310) 652-9162

Michael Marvin Levine, M.D., F.A.C.P.

Personal

Place of Birth

Harrisburg, Pennsylvania


Education

1971 - 1975

B.A. in Chemistry, Oberlin College, Oberlin, Ohio
Graduated with Honor

1975-1978

M.D., Baylor College of Medicine, Houston, Texas
Graduated with High Honor


Professional Training And Experience

1979-1980

Straight Medicine Internship, UCLA-CHS, Los Angeles, California

1980-1982

Residency, Internal Medicine, UCLA-CHS, Los Angeles, California

1982-1983

Nephrology Fellowship, UCSF, San Francisco, California

1983-1984

Nephrology Fellowship, UCLA-CHS, Los Angeles, California

1984-1986

Clinical Instructor in Medicine, UCLA Medical School

1987-present

Clinical Associate Professor of Medicine, UCLA Medical School
Attending Staff, Cedars-Sinai Medical Center

1985-present

Tower Nephrology


Professional Qualifications

Internal Medicine

Diplomate, American Board of Internal Medicine, 1983

Nephrology

Board Certified in Subspecialty of Nephrology, 1985


Professional Societies

  • Alpha Omega Alpha
  • Fellow, American College of Physicians, 1991
  • American Society of Nephrology
  • Los Angeles County Medical Association
  • Member, American Society of Internal Medicine

Publications

  • Shapiro, M., Levine, M., Makoff, R., and Bricker, N.S., .The Sodium Control System., in Current Nephrology (H. Gonick, ed.), New York, Year Book Publishers, 1986.
  • Shapiro, M., Levine, M.M. and Bricker, N.S., .The Renal Response to Nephron Loss., in Physiology and Pathology of Electrolyte Metabolism, (D. Seldin and G. Giebisch, ed.), New York, Plenum Publishing Co., 1987.
  • Levine, M.M., Kirschenbaum, M.A., Choudhari, A., Wong, M.W., and Bricker, N.S., .Effect of Protein on Glomerular Filtration Rate and Prostanoid Synthesis in Normal and Uremic Rats.. American Journal of Physiology, 251 (Renal Fluid Electrolyte Physiol. 20); F635-F641, 1986.
  • Levine, M.M., Kleeman, K.E., and Kleeman, C.R., .Pathophysiology of Hypercalcemia., Hospital Practice, 22: 93-110, 1987.

Clinical Study Location

  • Tower Nephrology Medical Group, 8635 W. 3RD ST #485W Los Angeles, CA 90048
  • DaVita of Beverly Hills, 50 N. La Cienega blvd. #300 Beverly hills, CA 90211
  • DaVita of Crescent Heights, 8151 Beverly blvd Los Angeles, CA 90048

Clinical Studies

2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)

Sub-Investigator 2014 Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis
Sub-Investigator 2014 A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Sub-Investigator 2013 A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis.
Sub-Investigator 2013 ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.
Sub-Investigator 2013 Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease.
Sub-Investigator 2013 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137
Sub-Investigator 2012 A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy
Sub-Investigator 2011 A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Sub-Investigator 2011 Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon)
Sub-Investigator 2011 A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study

2010 GCP Certified by the National Cancer Institute

Principal Investigator 2010

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Sub-Investigator 2010

Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism.

Principal Investigator 2009

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

Principal Investigator 2008

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

Principal Investigator 2007

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

Sub-Investigator 2007

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

Principal Investigator 2007

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

Sub-Investigator 2007

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

Principal Investigator 2007

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

Sub-Investigator 2007

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

Sub-Investigator 2007

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

Sub-Investigator 2007

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

Sub-Investigator 2006

A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

Sub-Investigator 2006

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

Sub-Investigator 2006

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

Principal Investigator 2005

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

Sub-Investigator 2004

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

Sub-Investigator 2004

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.

Sub-Investigator 2003

Phase 3 Cinacalcet open label to reach K/DOQI levels

Sub-Investigator 2003

Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce.

Sub-Investigator 2003

Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

Sub-Investigator 2003

Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Principal Investigator 2002

Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW).

Sub-Investigator 2002

Phase 3 Placebo-controlled, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease.

Principal Investigator 2002

Phase 4 Disease/Case Management of Patients Receiving ARANESP (darbepoetin alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 4, Multicenter Trial Using Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) and Iron Guided Algorithms to Treat Subjects with Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 4 Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) in subjects with Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent on Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis.

Sub-Investigator 2001

Phase 3 A Multicenter, Open-label Extension Study to Assess the Long- term Safety and Efficacy if an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Sub-Investigator 2001

Phase 2 Randomized, double-blind Study to Assess the Efficacy and safety of an Oral Calcimimetic Agent on secondary Hyperparathyroidism of End Stage Renal Disease treated with Hemodialysis.

Sub-Investigator 2000

Phase 2 Pharmacokinetic (PK) Analysis of Chronic Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis (HD).

Principal Investigator 1999

Chronic Renal Insufficiency registry in a prospective, observational study designed to gather data on the use of various interventions delivered to patients with renal insufficiency, pre-ESRD.

Sub-Investigator 1999

Randomized Study Comparing the Efficiency of Once Weekly Versus 3 Times Weekly Administration of Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) to Subjects with End-Stage Renal Disease Receiving Hemodialysis.